Aakash Babu

Aakash has covered the pharma sector since 2018, writing on everything from clinical trial successes to industry setbacks that offer lessons for those who follow. He enjoys travelling, supports Manchester United, and is an avid gamer.

Page 1 of 2

an image of a gold and black trophy placed in front of a white background

Therapeutic Thursday: Plasters, Stitches And A $57bn War Chest

Novo Nordisk absorbs two trial failures and signals bolt-on deals, while Eli Lilly counts 31 transactions in seven months this year as it plays offense without the pressure of having to “buy revenue”.

Aug 6, 2026 Aakash Babu 6 min read members

A pile of money sitting on top of a table.

Therapeutic Thursday: GSK Bets Big, And Europe's Pricing Problem Gets A Face

An ADC with ambitions across five tumor types. A £1.9bn cost cut to fund a pipeline push. And a breast cancer drug caught between a stalled FDA review and a European pricing standoff.

Jul 30, 2026 Aakash Babu 5 min read members

Overhead shot of a sunlit beach, turquoise water breaking onto white sand dotted with a few red and teal umbrellas, evoking a heatwave week.

The Long View: Europe Sends A Warning, Japan Sends A Number

Two would-be contenders answered the same question this week, how to stay relevant when you are not the United States, and they answered it in different currencies: one in words, one in yen.